ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Accolade Announces Results for Fiscal Second Quarter 2022

October 7, 2021 GMT

  • Fiscal second quarter 2022 revenue of $73.3 million, a 99% increase compared to fiscal second quarter 2021 revenue of $36.8 million 
  • Introduced Personalized Healthcare category, focused on human relationships and personalization using data to enable value-based care
  • Launched Accolade One and Accolade Care, two new healthcare solutions that combine Accolade’s intelligent technology, advocacy services and team-based healthcare delivery

SEATTLE, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2021.

“At Accolade, we believe it is time for a new approach that recognizes healthcare is a personal experience, and that we must stop rewarding a system that fundamentally doesn’t work for patients or employers. At our recent Evolve21 customer conference, we were proud to introduce Personalized Healthcare, a new category that enables a nationally scalable model of value-based care. Personalized Healthcare requires all healthcare companies to step up and offer solutions that deliver a personalized experience, are powered by data-driven insights, and align the financial model with demonstrated value. Our new solutions – Accolade One and Accolade Care – deliver one of the broadest offering portfolios available to employers,” said Rajeev Singh, Accolade Chief Executive Officer.

ADVERTISEMENT

Accolade also announced today that it completed the acquisition of substantially all the assets of HealthReveal, a clinical artificial intelligence (AI) company focused on ensuring patients receive optimal, personalized chronic care to preempt adverse outcomes. HealthReveal’s technology continually applies the latest medical guidelines to produce Reveals – personalized diagnostic and treatment recommendations. The addition of HealthReveal’s technology and team will accelerate Accolade’s focus on providing data-driven, clinically-based recommendations to our frontline care teams of physicians, specialists, nurses and health assistants.  

Financial Highlights for Fiscal Second Quarter ended August 31, 2021

ADVERTISEMENT
         
  Three Months Ended August 31, %
     2021    2020    Change(2)
  (in millions, except percentages)  
GAAP Financial Data:        
Revenue $73.3  $36.8  99%
Net Loss $(62.4) $(15.4) (306)%
         
Non-GAAP Financial Data(1):        
Adjusted EBITDA $(19.4) $(8.7) (122)%
Adjusted Gross Profit $30.0  $15.9  88%
Adjusted Gross Margin  40.9%  43.3%  

(1) A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying Financial Tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

(2) Percentages are calculated from accompanying Financial Tables and may differ from percentage change of numbers in Financial Highlights table due to rounding.

Financial Outlook

Accolade provides forward-looking guidance on revenue and Adjusted EBITDA, a non-GAAP financial measure.

For the fiscal third quarter ending November 30, 2021, we expect:

  • Revenue between $74.5 million and $76.5 million, which includes approximately $2.5 million of performance guarantee revenue that is expected to be recognized in the fiscal third quarter that was previously expected to be recognized in the fiscal fourth quarter
  • Adjusted EBITDA between $(21.5) million and $(24.5) million

For the fiscal year ending February 28, 2022, we are revising our revenue and reaffirming our Adjusted EBITDA ranges as follows:

  • Revenue between $303 million and $307 million
  • Adjusted EBITDA between $(49) million and $(54) million

Commenting on the company’s results and revised fiscal year 2022 outlook, Accolade Chief Financial Officer Steve Barnes added, “Our second quarter results demonstrated the consistency and predictability of Accolade’s business. We are beginning to see the positive impact of combining Accolade, 2nd.MD and PlushCare, with the teams operating as one across all areas, especially sales and product development. As we have consistently said previously, we plan to invest in the integration between the three offerings to maintain a superlative member and customer experience. We will continue to focus driving top line growth while demonstrating consistent progress toward our long-term operating model.”

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably predicted.

Quarterly Conference Call Details 

The company will host a conference call today, October 7, 2021 at 4:30 p.m. E.T. to discuss its financial results. The conference call can be accessed by dialing 1-833-519-1281 for U.S. participants, or 1-914-800-3853 for international participants, referencing conference ID # 9547326; or via a live audio webcast that will be available online at http://ir.accolade.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Forward-Looking Statements 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “likely,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risks described under the heading “Risk Factors” in Accolade’s most recently filed Quarterly Report on Form 10-Q, which should be read in conjunction with any forward-looking statements. All forward-looking statements in this press release are based on information available to Accolade as of the date hereof, and it does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

About Accolade, Inc. 

Accolade (Nasdaq: ACCD) provides millions of people and their families with an exceptional healthcare experience that is personal, data driven and value based to help every person live their healthiest life. Accolade solutions combine virtual primary care, mental health support and expert medical opinion services with intelligent technology and best-in-class care navigation. Accolade’s Personalized Healthcare approach puts humanity back in healthcare by building relationships that connect people and their families to the right care at the right time to improve outcomes, lower costs and deliver consumer satisfaction. Accolade consistently receives consumer satisfaction ratings over 90%. For more information, visit accolade.com.

Investor Contact:

Todd Friedman, Investor Relations, IR@accolade.com

Asher Dewhurst, Investor Relations, Accolade@westwicke.com

Media Contact:

Megan Torres, Public Relations, Media@accolade.com

Source: Accolade

Financial Tables

       
Accolade, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (unaudited)
(In thousands, except share and per share data)
       
  August 31,  February 28, 
  2021 2021
Assets      
Current assets:      
Cash and cash equivalents $384,003  $433,884 
Accounts receivable, net  15,845   9,112 
Unbilled revenue  2,875   2,725 
Current portion of deferred contract acquisition costs  2,864   2,210 
Current portion of deferred financing fees     93 
Prepaid and other current assets  12,023   5,957 
Total current assets  417,610   453,981 
Property and equipment, net  12,181   9,227 
Goodwill  575,660   4,013 
Intangible assets, net  255,166   604 
Deferred contract acquisition costs  7,256   6,067 
Other assets  1,921   1,618 
Total assets $1,269,794  $475,510 
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable $8,696  $7,390 
Accrued expenses  6,777   4,845 
Accrued compensation  35,868   35,379 
Deferred rent and other current liabilities  3,040   567 
Due to customers  6,685   5,015 
Current portion of deferred revenue  43,117   25,879 
Contingent consideration liabilities  145,214    
Total current liabilities  249,397   79,075 
Convertible notes, net of unamortized issuance costs  279,849    
Deferred rent and other noncurrent liabilities  6,637   5,192 
Deferred revenue  353   395 
Total liabilities  536,236   84,662 
       
Commitments and Contingencies      
Stockholders’ equity      
Common stock par value $0.0001; 500,000,000 shares authorized; 66,348,000 and 55,699,052 shares issued and outstanding at August 31, 2021 and February 28, 2021, respectively  7   6 
Additional paid-in capital  1,216,142   762,362 
Accumulated deficit  (482,591)  (371,520)
Total stockholders’ equity  733,558   390,848 
Total liabilities and stockholders’ equity $1,269,794  $475,510 
             
Accolade, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (unaudited)
(In thousands, except share and per share data)
             
  Three months ended August 31,  Six months ended August 31, 
     2021    2020    2021    2020
Revenue $73,288  $36,788  $132,815  $72,682 
Cost of revenue, excluding depreciation and amortization  44,334   21,071   80,270   43,310 
Operating expenses:            
Product and technology  22,512   12,236   38,451   23,606 
Sales and marketing  24,009   7,881   38,518   15,196 
General and administrative  26,170   6,453   48,172   12,120 
Depreciation and amortization  11,021   2,049   19,717   3,977 
Change in fair value of contingent consideration  19,686      30,146    
Total operating expenses  103,398   28,619   175,004   54,899 
Loss from operations  (74,444)  (12,902)  (122,459)  (25,527)
Interest expense, net  (776)  (2,347)  (1,394)  (3,629)
Other income (expense)  11   (104)  (44)  (119)
Loss before income taxes  (75,209)  (15,353)  (123,897)  (29,275)
Income tax benefit (expense)  12,845   (18)  12,826   (56)
Net loss $(62,364) $(15,371) $(111,071) $(29,331)
             
Net loss per share, basic and diluted $(0.97) $(0.47) $(1.81) $(1.45)
             
Weighted-average common shares outstanding, basic and diluted  64,404,223   33,029,147   61,332,729   20,277,416 
                 

The following table summarizes the amount of stock-based compensation included in the condensed consolidated statements of operations:

             
  Three months ended August 31,  Six months ended August 31, 
     2021    2020     2021    2020
Cost of revenue, excluding depreciation and amortization $1,054 $218 $1,382 $327
Product and technology  6,366  718  8,188  1,152
Sales and marketing  4,054  490  5,427  792
General and administrative  8,301  679  12,453  1,093
Total stock-based compensation $19,775 $2,105 $27,450 $3,364
       
Accolade, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
(In thousands)
       
  Six months ended August 31, 
     2021    2020
Cash flows from operating activities:      
Net loss $(111,071) $(29,331)
Adjustments to reconcile net loss to net cash used in      
Operating activities:      
Depreciation and amortization expense  19,717   3,977 
Amortization of deferred contract acquisition costs  1,246   740 
Change in fair value of contingent consideration  30,146    
Deferred income taxes  (12,865)   
Noncash interest expense  823   1,316 
Stock-based compensation expense  27,450   3,364 
Changes in operating assets and liabilities, net of effect of acquisitions:      
Accounts receivable and unbilled revenue  1,440   (9,581)
Accounts payable and accrued expenses  (267)  (806)
Deferred contract acquisition costs  (2,349)  (2,812)
Deferred revenue and due to customers  16,735   3,847 
Accrued compensation  (5,782)  6,580 
Deferred rent and other liabilities  (75)  (212)
Other assets  (3,792)  (437)
Net cash used in operating activities  (38,644)  (23,355)
Cash flows from investing activities:      
Purchase of marketable securities  (99,998)   
Sale of marketable securities  99,998    
Capitalized software development costs  (356)  (374)
Purchases of property and equipment  (1,573)  (981)
Earnout payments to MD Insider     (58)
Cash paid for acquisitions, net of cash acquired  (261,873)   
Net cash used in investing activities  (263,802)  (1,413)
Cash flows from financing activities:      
Proceeds from IPO, net of underwriters' discounts and commissions and offering costs     231,675 
Proceeds from stock option and warrant exercises  5,654   4,802 
Payments of equity issuance costs  (60)   
Payment of debt issuance costs  (8,368)   
Payment for purchase of capped calls  (34,443)   
Proceeds from stock purchases under employee stock purchase plan  2,282    
Proceeds from borrowings on debt  287,500   51,166 
Repayments of debt principal     (73,166)
Payments related to debt retirement     (753)
Net cash provided by financing activities  252,565   213,724 
Net increase (decrease) in cash and cash equivalents  (49,881)  188,956 
Cash and cash equivalents, beginning of period  433,884   33,155 
Cash and cash equivalents, end of period $384,003  $222,111 
Supplemental cash flow information:      
Interest paid $102  $2,194 
Fixed assets included in accounts payable $166  $48 
Other receivable related to stock option exercises $75  $108 
Income taxes paid $60  $105 
Common stock issued in connection with acquisitions $446,525  $ 
Replacement awards issued in connection with acquisitions $6,729  $ 
Bonus settled in the form of stock options $  $5,735 
Debt issuance and offering costs included in accounts payable and accrued expenses $  $312 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we use the following non-GAAP financial measures to help us evaluate trends, establish budgets, measure the effectiveness and efficiency of our operations, and determine employee incentives. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors, as they eliminate the impact of certain noncash expenses and allow a direct comparison of these measures between periods without the impact of noncash expenses and certain other nonrecurring operating expenses.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted to exclude interest expense (net), income tax expense (benefit), depreciation and amortization, stock-based compensation, acquisition and integration-related costs, and change in fair value of contingent consideration. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this measure generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA have certain limitations, including that they exclude the impact of certain non-cash charges, such as depreciation and amortization, whereas underlying assets may need to be replaced and result in cash capital expenditures, and stock-based compensation expense, which is a recurring charge. These non-GAAP financial measures may also not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner, limiting their usefulness as comparative measures. In evaluating these non-GAAP financial measures, you should be aware that in the future we expect to incur expenses similar to the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation tables below and our other GAAP results. The following table presents, for the periods indicated, a reconciliation of our revenue to Adjusted Gross Profit:

             
  For the three months ended For the six months ended
  August 31,  August 31, 
  2021     2020
  2021
    2020
  (in thousands, except percentages) (in thousands, except percentages)
Revenue $73,288  $36,788  $132,815  $72,682 
Less:            
Cost of revenue, excluding depreciation and amortization  (44,334)  (21,071)  (80,270)  (43,310)
Gross profit, excluding depreciation and amortization  28,954   15,717   52,545   29,372 
Add:            
Stock‑based compensation, cost of revenue  1,054   218   1,382   327 
Adjusted Gross Profit $30,008  $15,935  $53,927  $29,699 
Gross margin, excluding depreciation and amortization  39.5%  42.7%  39.6%  40.4%
Adjusted Gross Margin  40.9%  43.3%  40.6%  40.9%
             

The following table presents, for the periods indicated, a reconciliation of our Adjusted EBITDA to our net loss:

             
  For the three months ended For the six months ended
  August 31,  August 31, 
  2021    2020    2021    2020
  (in thousands) (in thousands)
Net Loss $(62,364) $(15,371) $(111,071) $(29,331)
Adjusted for:                
Interest expense, net  776   2,347   1,394   3,629 
Income tax expense (benefit)  (12,845)  18   (12,826)  56 
Depreciation and amortization  11,021   2,049   19,717   3,977 
Stock‑based compensation  19,775   2,105   27,450   3,364 
Acquisition and integration‑related costs  4,517      12,897    
Change in fair value of contingent consideration  19,686      30,146    
Other expense (income)  (11)  104   44   119 
Adjusted EBITDA $(19,445) $(8,748) $(32,249) $(18,186)